Psoriatic Arthritis

Retention rates for golimumab treatment at the 5-year mark were consistently high when used as a first-line therapy and did not significantly differ across conditions.

Investigators found intestinal permeability and fecal and plasma metabolomic profiles of patients with PsA in the FLORA trial cohort were associated with clinical response to FMT.

Patients with SARS-CoV-2 infection experienced a 22% increase in the incidence of immune-mediated inflammatory diseases, including T1DM, IBD, and psoriasis.

Most patients were able to achieve clear or almost clear skin, and improvement of arthritis and difficult-to-treat areas, with guselkumab and risankizumab treatment.

Of the 333 patients with PsA and 457 patients with axSpA, there were 1.09 serious infections per 100 patient years (95% CI .85 – 1.35).

Patients diagnosed with psoriatic arthritis and obesity were older, more frequently women, had worse pain, physical function, and health-related quality of life, and had higher tender joint and enthesitis counts when compared with nonobese patients.

Of the 130 patients with psoriatic arthritis who participated in a telemedicine assessment, 83% were happy with the consultation.

A recent study found initial monotherapy for chronic inflammatory arthritis yields better treatment persistence and safety relative to combination therapy.

At week 52, patients in the bimekizumab cohort demonstrated sustained clinical responses, which were consistent with results reported at week 16.

A study on juvenile idiopathic arthritis emphasizes early initiation of biologic treatment for better long-term outcomes, as delayed treatment is linked to greater physical disability and worse quality of life in adulthood.

High-intensity interval training appears safe for individuals with psoriatic arthritis, as a study found no significant increase in inflammation assessed by ultrasound and MRI.

In patients receiving guselkumab, achieving NAPSI 0/1 at week 24 and week 48 was associated with lower baseline NAPSI and week 16 PASI.

In this Q&A, Vinod Chandran, MBBS, MD, DM, PhD, discussed a method to analyze biomarkers that may differentiate patients with psoriasis and psoriatic arthritis.

This retrospective study from Japan highlighted several key elements linked to a generalized pustular psoriasis diagnosis among individuals with psoriasis vulgaris.

This small study found DNA methylation profiles in CD4+ T-cells may represent a stable and reliable biomarker.

Significantly greater improvements in back pain and morning stiffness were observed in patients receiving ixekizumab compared with placebo.

Continued reductions in serum acute phase proteins and collagen degradation proteins observed in patients with psoriatic arthritis receiving guselkumab may be linked to sustained symptom improvements.

An interim analysis from the UPJOINT trial provides insight into the effects of upadacitinib use in real-world settings among patients with oligo- or polyarticular psoriatic arthritis.

Investigators believe a more consistent application of disease activity measures may help to guide treatment decisions and improve quality of care.

A higher number of patients receiving guselkumab treatment reported ≥1 improvement as early as week 4, which continued to improve through week 24.

Real-world analyses help patients and their healthcare providers make more informed and personalized treatment decisions with the goal of long-term symptomatic relief.

At week 24, patients receiving guselkumab had significant decreases in C-reactive protein and effector cytokines linked to the interleukin-23 (IL-23)/IL-17 levels compared with patients in the placebo cohort.

Researchers report on the global real-world safety profile of tofacitinib in psoriatic arthritis.

Findings reveal a need for distinct strategies to prevent cardiovascular events in patients with rheumatoid arthritis and psoriatic arthritis.

At weeks 12 and 24, the proportion of patients reporting high disease activity reduced from 16.7% to 8.3%, respectively.

This systematic review found 26 DMARDs in clinical development for spondyloarthritis, including psoriatic arthritis, but their target diversity was low.

According to the PRESTO tool, the risk of developing psoriatic arthritis in patients with psoriasis within 1 year was linked to a family history of psoriasis, joint or back stiffness, male sex, younger age, pain severity, and the use of biologic medications.

Changes in BMI were positively correlated with changes in IL-23 and significant positive correlations were observed between BMI and DAS28-CRP, CRP, IL-13, IL-17, leptin, and TNF-α.

Patients with JPsA and concomitant psoriasis at diagnosis exhibited more depressive symptoms when compared with those without psoriasis.

In the updated analysis, the interleukin-23 p19-subunit inhibitor also showed better skin efficacy.